Please login to the form below

Not currently logged in


This page shows the latest monalizumab news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca and Innate Pharma to end study on immuno-oncology drug monalizumab

AstraZeneca and Innate Pharma to end study on immuno-oncology drug monalizumab

We continue to explore the impact of monalizumab in patients with non-small cell lung cancer across different trials, including the phase 3 PACIFIC-9 trial.”. ... AZ obtained full oncology right to monalizumab in October 2018 by utilising its option

Latest news

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    AstraZeneca. Anti-NKG2A antibody (monalizumab), IPH5201 (antibody targeting CD38) and Lumoxiti. #. for hairy cell leukaemia. Development &. commercialisation. collaboration. $307m. ViraTherapeutics/. Boehringer Ingelheim.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts


Add my company
Thrive Agency

We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...

Latest intelligence

New Playbook Alert: Virtual Patient Engagement
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....